Thrombotic Microangiopathy (TMA) encompasses a group of rare but severe disorders characterized by the formation of blood clots in small blood vessels, leading to organ damage and dysfunction. These conditions, including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), pose significant clinical challenges due to their complex pathophysiology and potentially life-threatening consequences. Given the limited understanding of TMA's underlying mechanisms, there's a critical need for innovative therapeutic strategies to improve patient outcomes and reduce morbidity and mortality. This collection aims to explore the latest advancements in therapeutic approaches for TMA, ranging from novel pharmacological agents to innovative treatment modalities. By compiling cutting-edge research and insights from experts in the field, this Research Topic seeks to provide a comprehensive overview and guide for clinicians and researchers striving to enhance TMA management.
In this Research Topic, we welcome articles focusing on:
Novel pharmacological agents targeting specific pathways involved in TMA pathogenesis.
Innovative treatment modalities, including immunomodulatory therapies and targeted biologics, for TMA management.
Therapeutic approaches aimed at preventing or resolving organ damage associated with TMA.
Clinical trials evaluating the efficacy and safety of emerging treatments for TMA.
Strategies for optimizing current treatment regimens and improving patient outcomes in TMA.
Translational research bridging basic science discoveries with clinical applications in TMA therapeutics.
Multidisciplinary perspectives on TMA management, including contributions from hematologists, nephrologists, and other relevant specialists.
Case reports illustrating unique or challenging aspects of TMA diagnosis and treatment.
Reviews summarizing the current state of knowledge and future directions in TMA therapeutics.
We aim for this Research Topic to contribute to advancing our understanding of TMA pathophysiology and improving clinical outcomes for patients affected by these challenging disorders. We welcome a variety of article types, including under the following categories: Original Research, Review, Mini Review, Brief Research Report, and Perspective.
Keywords:
Thrombotic Microangiopathy, TMA, Blood Clots, Blood Vessels, Thrombotic Thrombocytopenic Purpura, TTP, Hemolytic Uremic Syndrome, HUC
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Thrombotic Microangiopathy (TMA) encompasses a group of rare but severe disorders characterized by the formation of blood clots in small blood vessels, leading to organ damage and dysfunction. These conditions, including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), pose significant clinical challenges due to their complex pathophysiology and potentially life-threatening consequences. Given the limited understanding of TMA's underlying mechanisms, there's a critical need for innovative therapeutic strategies to improve patient outcomes and reduce morbidity and mortality. This collection aims to explore the latest advancements in therapeutic approaches for TMA, ranging from novel pharmacological agents to innovative treatment modalities. By compiling cutting-edge research and insights from experts in the field, this Research Topic seeks to provide a comprehensive overview and guide for clinicians and researchers striving to enhance TMA management.
In this Research Topic, we welcome articles focusing on:
Novel pharmacological agents targeting specific pathways involved in TMA pathogenesis.
Innovative treatment modalities, including immunomodulatory therapies and targeted biologics, for TMA management.
Therapeutic approaches aimed at preventing or resolving organ damage associated with TMA.
Clinical trials evaluating the efficacy and safety of emerging treatments for TMA.
Strategies for optimizing current treatment regimens and improving patient outcomes in TMA.
Translational research bridging basic science discoveries with clinical applications in TMA therapeutics.
Multidisciplinary perspectives on TMA management, including contributions from hematologists, nephrologists, and other relevant specialists.
Case reports illustrating unique or challenging aspects of TMA diagnosis and treatment.
Reviews summarizing the current state of knowledge and future directions in TMA therapeutics.
We aim for this Research Topic to contribute to advancing our understanding of TMA pathophysiology and improving clinical outcomes for patients affected by these challenging disorders. We welcome a variety of article types, including under the following categories: Original Research, Review, Mini Review, Brief Research Report, and Perspective.
Keywords:
Thrombotic Microangiopathy, TMA, Blood Clots, Blood Vessels, Thrombotic Thrombocytopenic Purpura, TTP, Hemolytic Uremic Syndrome, HUC
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.